It requires a delicate balance between optimizing maternal oncologic outcomes and ensuring fetal safety.<h4>Case presentation</h4>We report the case of a 33-year-old woman diagnosed with HER-2 overexpressing invasive ductal carcinoma of the right breast at 16 weeks of gestation. This evidence concerns the gene ERBB2 and invasive ductal breast carcinoma.